VARYING REACTIVITIES OF MONOCLONAL ANTIBODIES WITH THE SAME POLIO VACCINE

我们已经建立了一种灵敏的ELISA法来测量细胞的效力 用鼠单抗制备脊髓灰质炎病毒三价疫苗 抗原检测。在IPV的常规测试中，我们发现了一种疫苗 第二类成分用我们的标准试剂检测非常低；但是 与另一种2型单抗或兔的结果令人满意 多克隆血清。我们正在与另一家实验室合作，作为 单独的研究项目，以确定我们的网站的特殊性 单克隆抗体。我们正在试图澄清 这一明显的表位特异性变化的原因类型2组分 很多疫苗都通过了酶联免疫吸附试验。我们回顾了相关文献。 已知会影响脊髓灰质炎病毒效力的化学物质。我们正在研究 硫柳汞和其他防腐剂组合的效果。EDTA， 2-苯氧基乙醇和甲醛对IPV效力的影响。准备工作已经完成 在37、25和40摄氏度三种温度下保存2周。这个 在第2天、第10天和第14天用酶联免疫吸附试验检测制剂的效力。 在37℃和40℃保存的疫苗制剂接种小鼠一天 14.通过观察疫苗在体内的效力，我们将获得 更好地理解ELISA检测到的效力下降是否 反映在小鼠的免疫原性降低。此外，我们正在寻找 硫柳汞与硫柳汞混合疫苗对效力的影响 灭活脊髓灰质炎病毒疫苗。这些发现将对汽车制造商产生重要影响。 因为它们将需要考虑每种疫苗的效果 在混合物中的抗原上添加防腐剂。

We have developed a sensitive ELISA assay for measuring the potency of trivalent poliovirus vaccines using mouse monoclonal antibodies for antigen detection. During routine tests of IPV we found a vaccine lot the type 2 component of which tested very low with our standard reagent; but gave satisfactory values with another type 2 monoclonal antibody or rabbit polyclonal sera. We are collaborating with another laboratory as a separate research project to identify the site specificity of our monoclonal antibodies. We are in the process of trying to elucidate the cause for this apparent epitope specific change in the type 2 component of lots of vaccine which passed in the ELISA test. We reviewed the literature for chemicals known to affect the potency of poliovirus. We are examining the effect of thimerosal and other combinations of preservatives eg. EDTA, 2-phenoxyethanol and formaldehyde on the potency of IPV. Preparations have been held at three temperatures 37, 25 and 40C for 2 weeks. The preparations were tested for potency by ELISA at 2, 10, and 14 days. Vaccine preparations held at 37 and 40C were inoculated into mice on day 14. By looking at the potency of the vaccines in vivo we will have a better understanding of whether the drop in potency detected by ELISA is reflected in a lowered immunogenicity in mice. In addition, we are looking at the effect on potency of mixing vaccines containing thimerosal with IPV. These findings will have important implications for manufacturers of combination vaccines as they will need to consider the effect of each preservative on the antigens in the combination.